EIKN — Eikon Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $322.12m
- $322.12m
- 12
- 35
- 32
- 14
Annual cashflow statement for Eikon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -242 | -244 |
| Depreciation | ||
| Amortisation | ||
| Non-Cash Items | 23.4 | 2.97 |
| Other Non-Cash Items | ||
| Changes in Working Capital | 9.98 | 80.7 |
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | -191 | -135 |
| Capital Expenditures | -28.5 | -84.8 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | 165 | 236 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | 137 | 151 |
| Net Issuance / Retirement of Stock | ||
| Cash from Financing Activities | 106 | 0.244 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 51.9 | 16.8 |